La leptine, nouvelle perspective thérapeutique dans le traitement du diabète ?

Camille Vatier; Jacqueline Capeau; Corinne Vigouroux

doi:10.1051/medsci/20102610803

Accueil

Tous les numéros

Volume 26 / Numéro 10 (Octobre 2010)

Med Sci (Paris), 26 10 (2010) 803-807

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 26, Numéro 10, Octobre 2010


Page(s)		803 - 807
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20102610803
Publié en ligne		15 octobre 2010

Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009 ; 297 : E1247-59. [Google Scholar]
Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999 ; 341 : 879-84. [Google Scholar]
Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002 ; 110 : 1093-103. [Google Scholar]
Capeau J, Magré J, Caron-Debarle M, et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr Dev 2010 ; 19 : 1-20. [Google Scholar]
Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med, 2002 ; 346 : 570-8. [Google Scholar]
Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002 ; 109 : 1345-50. [Google Scholar]
Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010 : 53 : 27-35. [Google Scholar]
Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 2007 ; 120 : e291-6. [Google Scholar]
Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010 ; 1801 : 209-14. [Google Scholar]
Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptin replacement therapy in Berardinelli-Seip congenital lipodystrophy (BSCL): an immunological origin. Eur J Endocrinol 2010 ; 162 : 1083-91. [Google Scholar]
Kusakabe T, Tanioka H, Ebihara K, et al. Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 2009 ; 52 : 675-83. [Google Scholar]
Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004 ; 53 (suppl 1) : S152-8. [Google Scholar]
Park S, Ahn IS, Kim da S. Central infusion of leptin improves insulin resistance and suppresses beta-cell function, but not beta-cell mass, primarily through the sympathetic nervous system in a type 2 diabetic rat model. Life Sci 2010 ; 86 : 854-62. [Google Scholar]
Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010 ; 107 : 4813-9. [Google Scholar]
Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999 ; 48 : 1487-92. [Google Scholar]
Miyanaga F, Ogawa Y, Ebihara K, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 2003 ; 46 : 1329-37. [Google Scholar]
Yu X, Park BH, Wang MY, et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008 ; 105 : 14070-5. [Google Scholar]
Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008 ; 117 : 3238-49. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009 ; 297 : E1247-59. [Google Scholar]

[2] Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999 ; 341 : 879-84. [Google Scholar]

[3] Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002 ; 110 : 1093-103. [Google Scholar]

[4] Capeau J, Magré J, Caron-Debarle M, et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr Dev 2010 ; 19 : 1-20. [Google Scholar]

[5] Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med, 2002 ; 346 : 570-8. [Google Scholar]

[6] Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002 ; 109 : 1345-50. [Google Scholar]

[7] Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010 : 53 : 27-35. [Google Scholar]

[8] Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 2007 ; 120 : e291-6. [Google Scholar]

[9] Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010 ; 1801 : 209-14. [Google Scholar]

[10] Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptin replacement therapy in Berardinelli-Seip congenital lipodystrophy (BSCL): an immunological origin. Eur J Endocrinol 2010 ; 162 : 1083-91. [Google Scholar]

[11] Kusakabe T, Tanioka H, Ebihara K, et al. Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 2009 ; 52 : 675-83. [Google Scholar]

[12] Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004 ; 53 (suppl 1) : S152-8. [Google Scholar]

[13] Park S, Ahn IS, Kim da S. Central infusion of leptin improves insulin resistance and suppresses beta-cell function, but not beta-cell mass, primarily through the sympathetic nervous system in a type 2 diabetic rat model. Life Sci 2010 ; 86 : 854-62. [Google Scholar]

[14] Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010 ; 107 : 4813-9. [Google Scholar]

[15] Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999 ; 48 : 1487-92. [Google Scholar]

[16] Miyanaga F, Ogawa Y, Ebihara K, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 2003 ; 46 : 1329-37. [Google Scholar]

[17] Yu X, Park BH, Wang MY, et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008 ; 105 : 14070-5. [Google Scholar]

[18] Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008 ; 117 : 3238-49. [Google Scholar]